Table 2 Threshold utility analysis using three-way combinations of health state utility values to estimate Q-TWiST confidence intervalsa

From: A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

TWiST utility

REL, TOX utilities

 

0.1, 0.9

0.2, 0.8

0.4, 0.6

0.5, 0.5

0.6, 0.4

0.8, 0.2

0.9, 0.1

1.0

11.96

11.00

8.98

8.00

7.00

5.01

4.02

 

(8.10–14.83)*

(7.42–13.79)*

(6.10–11.51)*

(5.43–10.50)*

(4.65–9.38)*

(2.72–7.55)*

(1.51–6.76)*

0.805

9.49

8.49

6.50

5.51

4.51

2.52

1.52

 

(6.48–11.83)*

(5.93–10.85)*

(4.46–8.58)*

(3.60–7.51)*

(2.67–6.54)*

(0.43–4.91)†

(−0.70–4.03)

       

NS

  1. Abbreviations: Q-TWiST=quality-adjusted time without symptoms of disease or toxicity, REL=disease relapse, TOX=toxicity, NS=not statistically significant (P=0.124).
  2. aQ-TWiST mean differences and associated 95% confidence intervals in parentheses were estimated using the non-parametric bootstrap method.
  3. *P<0.001.
  4. †P<0.05.
Back to article page